Will a breakthrough obesity treatment halve average BMI in trials by 2029?

The Next Frontier of Metabolic Medicine

Obesity research has entered a strange renaissance. Once dismissed as a lifestyle issue, it's now clearly a biochemical labyrinth ready to be decoded. New therapies are hitting receptors and pathways scientists barely mapped a decade ago.

Halving BMI in clinical trials sounds extravagant, almost theatrical, but not impossible. Gene-editing adjuncts and metabolic rewiring could push boundaries far faster than older drug classes ever managed.

My prediction: A treatment approaches the threshold but doesn't fully halve BMI on average. Still, the world celebrates a leap forward that reshapes public health strategies everywhere.